AgingResearch.NewsJoin free

CDC42 inhibition

Intervention

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab in 1 country
  • Funder: Deutsche Forschungsgemeinschaft
  • Animals1

Outcomes

2

α-synuclein oligomer abundance

no changein mice1

1 study

  1. CDC42 inhibition has no effect on α-synuclein oligomer abundance in mice.

    “the intervention did not affect the amount of α-syn oligomers in the animals, while still improving phenotypes.”

    Animalsanimals with Parkinson's disease symptomsshort-term

    Molecular aging is the main driver of Parkinson’s Disease

    bioRxiv (Cold Spring Harbor Laboratory)30 Aug 2025Preprint

More on α-synuclein oligomer abundance

Parkinson's disease symptoms

downin mice1

1 study

  1. CDC42 inhibition decreases parkinson's disease symptoms in mice.

    “PD symptoms, as well as the PD Signature, were significantly altered by a short-term pharmacological attenuation of the activity of the small RhoGTPase CDC42”

    Animalsanimals with Parkinson's disease symptomsshort-term

    Molecular aging is the main driver of Parkinson’s Disease

    bioRxiv (Cold Spring Harbor Laboratory)30 Aug 2025Preprint

Associations

1

Parkinson's disease transcriptional signature

mixedin mice1

1 study

  1. CDC42 inhibition is associated with Parkinson's disease transcriptional signature in mice.

    “PD symptoms, as well as the PD Signature, were significantly altered by a short-term pharmacological attenuation of the activity of the small RhoGTPase CDC42”

    Animalsanimals with Parkinson's disease symptomsshort-term

    Molecular aging is the main driver of Parkinson’s Disease

    bioRxiv (Cold Spring Harbor Laboratory)30 Aug 2025Preprint

More on Parkinson's disease transcriptional signature

Latest

Related